BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1][2] Zacks Style Scores - The Zacks Style Scores are indicators that assist investors in selecting stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum characteristics [3] - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] - The Growth Score evaluates stocks based on projected and historical earnings, sales, and cash flow to identify sustainable growth opportunities [5] - The Momentum Score helps investors capitalize on price trends by analyzing short-term price changes and earnings estimate shifts [6] - The VGM Score combines all three Style Scores, providing a comprehensive indicator for selecting stocks with attractive value, growth potential, and momentum [7] Zacks Rank - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to simplify portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B to maximize returns [11] - Stocks with lower ranks, even with high Style Scores, may still face downward price trends due to negative earnings forecasts [12] Company Spotlight: BioMarin Pharmaceutical - BioMarin Pharmaceutical Inc. specializes in developing treatments for severe medical conditions, primarily in children, and is currently rated 3 (Hold) with a VGM Score of A [14] - The company has a Momentum Style Score of B, with shares increasing by 0.5% over the past four weeks, and has seen upward revisions in earnings estimates for fiscal 2024 [15] - With a solid Zacks Rank and strong Style Scores, BioMarin is positioned as a noteworthy option for investors [16]